IL Therapeutics explained

IL Therapeutics Inc.

IL Therapeutics Inc. was previously owned by Western Life Sciences Venture Fund LP("Western Life Sciences") and in 2006 its shares were purchased by Pacgen Biopharmaceuticals Corporation ("Pacgen").[1] [2]

History

Saskatchewan Research Council operates a bioprocessing laboratory which facilitated biomedical research. IL Therapeutics was developed from research first begun at the Western College of Veterinary Medicine.

Pharmaceuticals

Currently IL Therapeutics is working on a drug candidate, IL-8(3-73)K11R/G31P ("PAC-G31P") for relief of Acute Respiratory Distress Syndrome (ARDS).[1] The Saskatchewan Research council, SRC also assisted with the funding of this project through the Agriculture Development Fund - SRC Industry Venture Fund.[3] With the successful progression of G31P, the University of Saskatchewan Industry Liaison Office (ILO) decided to commercialize a commercialize this new drug treatment. This research has been sponsored by a $3 million boost from the Western Life Sciences Venture Fund (WLS)[4]

See also

External links

Notes and References

  1. Pacgen Biopharmaceuticals Acquires IL Therapeutics Inc. . April 12, 2006 . https://web.archive.org/web/20110715032138/http://www.pacgenbiopharm.com/investor/pdfs/news_release20060412.pdf . July 15, 2011 . Pacgen Biopharmaceuticals . August 11, 2018.
  2. Web site: Pacgen Biopharmaceuticals Acquires IL Therapeutics Inc. . April 12, 2006 . Pacgen Biopharmaceuticals . August 11, 2018.
  3. Book: Saskatchewan Research Council 2005-2006 Annual Report . Sustainable Science Solutions . 7–8 . https://web.archive.org/web/20110706203650/http://www.src.sk.ca/store/account/download_file.cfm?productID=3483&freeDownloadID=538 . July 6, 2011 . August 11, 2018.
  4. Saskatoon and District Chamber of Commerce . U of S News Releases: U of S Spin-off gets $3 Million Boost to Develop Anti-inflammatory Drug . December 2004 . Business View . 3 . August 11, 2018.